Patents by Inventor Beat Ernst
Beat Ernst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220185838Abstract: The invention relates to carbohydrate ligands presenting the minimal Human Natural Killer-1 (HNK-1) epitope that bind to anti-MAG (myelin-associated glycoprotein) IgM antibodies, and their use in diagnosis as well as for the treatment of anti-MAG neuropathy. In particular, the invention relates to disaccharides of formula (I) and (II) wherein Z is optionally substituted phenyl, heteroaryl, arylcarbonyl, or heteroarylmethyl, and to therapeutically acceptable polymers comprising a multitude of substituents of formula (I) and/or formula (II), wherein Z is a bifunctional linker connecting the disaccharides to the polymer backbone.Type: ApplicationFiled: November 30, 2021Publication date: June 16, 2022Inventors: Beat Ernst, Ruben Herrendorff, Andreas Steck, Fan Yang
-
Publication number: 20220169790Abstract: The invention relates to carbohydrate ligands and moieties, respectively, mimicking glycoepitopes comprised by glycosphingolipids of the nervous system, particularly glycoepitopes comprised by glycosphingolipids of the cerebroside, the globoside-, the ganglioside- and the sulfoglucuronyl paragloboside type, which are bound by anti-glycan antibodies associated with neurological diseases. The invention further relates to the use of these carbohydrate ligands/moieties, in diagnosis as well as for the treatment of neurological diseases associated with anti-glycan antibodies. In particular, the invention relates to compounds of formula (I) and (II) and to therapeutically acceptable polymers comprising a multitude of these compounds, including polymers with loading of one compound of formula (I) or (II) or combinations of several compounds of formula (I), and/or (II).Type: ApplicationFiled: July 10, 2021Publication date: June 2, 2022Inventors: Ruben HERRENDORFF, Beat ERNST, Andreas STECK, Hélène PFISTER, Giulio NAVARRA
-
Patent number: 11220523Abstract: The invention relates to carbohydrate ligands presenting the minimal Human Natural Killer-1 (HNK-1) epitope that bind to anti-MAG (myelin-associated glycoprotein) IgM antibodies, and their use in diagnosis as well as for the treatment of anti-MAG neuropathy. In particular, the invention relates to disaccharides of formula (I) and (II) wherein Z is optionally substituted phenyl, heteroaryl, arylcarbonyl, or heteroarylmethyl, and to therapeutically acceptable polymers comprising a multitude of substituents of formula (I) and/or formula (II), wherein Z is a bifunctional linker connecting the disaccharides to the polymer backbone.Type: GrantFiled: April 14, 2020Date of Patent: January 11, 2022Assignee: UNIVERSITÄT BASELInventors: Beat Ernst, Ruben Herrendorff, Andreas Steck, Fan Yang
-
Patent number: 11091591Abstract: The invention relates to carbohydrate ligands and moieties, respectively, mimicking glycoepitopes comprised by glycosphingolipids of the nervous system, particularly glycoepitopes comprised by glycosphingolipids of the cerebroside, the globoside-, the ganglioside- and the sulfoglucuronyl paragloboside type, which are bound by anti-glycan antibodies associated with neurological diseases. The invention further relates to the use of these carbohydrate ligands/moieties, in diagnosis as well as for the treatment of neurological diseases associated with anti-glycan antibodies. In particular, the invention relates to compounds of formula (I) and (II) and to therapeutically acceptable polymers comprising a multitude of these compounds, including polymers with loading of one compound of formula (I) or (II) or combinations of several compounds of formula (I), and/or (II).Type: GrantFiled: September 14, 2016Date of Patent: August 17, 2021Assignee: UNIVERSITÄT BASELInventors: Ruben Herrendorff, Beat Ernst, Andreas Steck, Hélène Pfister, Giulio Navarra
-
Publication number: 20210061838Abstract: The invention relates to carbohydrate ligands presenting the minimal Human Natural Killer-1 (HNK-1) epitope that bind to anti-MAG (myelin-associated glycoprotein) IgM antibodies, and their use in diagnosis as well as for the treatment of anti-MAG neuropathy. In particular, the invention relates to disaccharides of formula (I) and (II) wherein Z is optionally substituted phenyl, heteroaryl, arylcarbonyl, or heteroarylmethyl, and to therapeutically acceptable polymers comprising a multitude of substituents of formula (I) and/or formula (II), wherein Z is a bifunctional linker connecting the disaccharides to the polymer backbone.Type: ApplicationFiled: April 14, 2020Publication date: March 4, 2021Inventors: Beat Ernst, Ruben Herrendorff, Andreas Steck, Fan Yang
-
Publication number: 20200316100Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed. For example, haloalkyl fucose-containing E-selectin antagonists and compositions comprising at least one such agent are described.Type: ApplicationFiled: May 22, 2017Publication date: October 8, 2020Applicant: GycoMimetics, Inc.Inventors: Beat ERNST, Norbert VARGA, Martin SMIESKO, Beatrice WAGNER, John M. PETERSON, John L. MAGNANI
-
Publication number: 20200171005Abstract: Compounds, compositions, and methods for modulating in vitro and in vivo processes mediated by selectin binding. For example, heterobifunctional compounds that inhibit both E-selectins and P-selectins are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids). The compounds are of formula (Ia) wherein the substituents are as defined in the claims.Type: ApplicationFiled: November 30, 2016Publication date: June 4, 2020Applicant: GlycoMimetics, Inc.Inventors: Beat ERNST, Beatrice WAGNER
-
Patent number: 10662212Abstract: The invention relates to carbohydrate ligands presenting the minimal Human Natural Killer-1 (HNK-1) epitope that bind to anti-MAG (myelin-associated glycoprotein) IgM antibodies, and their use in diagnosis as well as for the treatment of anti-MAG neuropathy. In particular, the invention relates to disaccharides of formula (I) and (II) wherein Z is optionally substituted phenyl, heteroaryl, arylcarbonyl, or heteroarylmethyl, and to therapeutically acceptable polymers comprising a multitude of substitutents of formula (I) and/or formula (II), wherein Z is a bifunctional linker connecting the disaccharides to the polymer backbone.Type: GrantFiled: May 11, 2018Date of Patent: May 26, 2020Assignee: UNIVERSITAT BASELInventors: Beat Ernst, Ruben Herrendorff, Andreas Steck, Fan Yang
-
Publication number: 20200079808Abstract: The invention relates to polymers comprising carbohydrate ligands and moieties, respectively, that bind to carbohydrate-binding proteins (CBPs), as well as to these carbohydrate ligands, and to their use in diagnosis and therapy of diseases that are associated with CBP-mediated cytotoxicity, agglutinatination, or immune complex deposit formation. In particular, the invention relates to polymers comprising a multitude of said carbohydrate ligands and moieties, respectively, mimicking carbohydrates that are bound by CBPs which belong to the group of (i) bacterial exotoxins, (ii) agglutinins, and (iii) immune complex deposit-forming immunoglobulins. Furthermore, the invention relates to the use of these polymers and carbohydrate ligands and moieties respectively, in diagnosis as well as for the treatment of diseases that are associated with CBP-mediated cytotoxicity, agglutinatination, or immune complex deposit formation. In one embodiment, the polymer is polylysine.Type: ApplicationFiled: March 15, 2018Publication date: March 12, 2020Inventors: Hélène Blanche PFISTER, Ruben HERRENDORFF, Beat ERNST
-
Publication number: 20180369205Abstract: Compounds, compositions, and methods for modulating in vitro and in vivo processes mediated by selectin binding. For example, heterobifunctional compounds that inhibit both E-selectins and P-selectins are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids). The compounds are of formula (Ia) wherein the substituents are as defined in the claims.Type: ApplicationFiled: November 30, 2016Publication date: December 27, 2018Applicant: GlycoMimetics, Inc.Inventors: Beat ERNST, Beatrice WAGNER
-
Publication number: 20180327438Abstract: The invention relates to carbohydrate ligands presenting the minimal Human Natural Killer-1 (HNK-1) epitope that bind to anti-MAG (myelin-associated glycoprotein) IgM antibodies, and their use in diagnosis as well as for the treatment of anti-MAG neuropathy. In particular, the invention relates to disaccharides of formula (I) and (II) wherein Z is optionally substituted phenyl, heteroaryl, arylcarbonyl, or heteroarylmethyl, and to therapeutically acceptable polymers comprising a multitude of substitutents of formula (I) and/or formula (II), wherein Z is a bifunctional linker connecting the disaccharides to the polymer backbone.Type: ApplicationFiled: May 11, 2018Publication date: November 15, 2018Inventors: Beat ERNST, Ruben HERRENDORFF, Andreas STECK, Fan YANG
-
Publication number: 20180251602Abstract: The invention relates to carbohydrate ligands and moieties, respectively, mimicking glycoepitopes comprised by glycosphingolipids of the nervous system, particularly glycoepitopes comprised by glycosphingolipids of the cerebroside, the globoside-, the ganglioside- and the sulfoglucuronyl paragloboside type, which are bound by anti-glycan antibodies associated with neurological diseases. The invention further relates to the use of these carbohydrate ligands/moieties, in diagnosis as well as for the treatment of neurological diseases associated with anti-glycan antibodies. In particular, the invention relates to compounds of formula (I) and (II) and to therapeutically acceptable polymers comprising a multitude of these compounds, including polymers with loading of one compound of formula (I) or (II) or combinations of several compounds of formula (I), and/or (II).Type: ApplicationFiled: September 14, 2016Publication date: September 6, 2018Applicant: Universitat BaselInventors: Ruben HERRENDORFF, Beat ERNST, Andreas STECK, Hélène PFISTER, Giulio NAVARRA
-
Patent number: 9994605Abstract: The invention relates to carbohydrate ligands presenting the minimal Human Natural Killer-1 (HNK-1) epitope that bind to anti-MAG (myelin-associated glycoprotein) IgM antibodies, and their use in diagnosis as well as for the treatment of anti-MAG neuropathy. In particular, the invention relates to disaccharides of formula (I) and (II) wherein Z is optionally substituted phenyl, heteroaryl, arylcarbonyl, or heteroarylmethyl, and to therapeutically acceptable polymers comprising a multitude of substituents of formula (I) and/or formula (II), wherein Z is a bifunctional linker connecting the disaccharides to the polymer backbone.Type: GrantFiled: March 12, 2015Date of Patent: June 12, 2018Assignee: UNIVERSITAET BASELInventors: Beat Ernst, Ruben Herrendorff, Andreas Steck, Fan Yang
-
Publication number: 20170022239Abstract: The invention relates to carbohydrate ligands presenting the minimal Human Natural Killer-1 (HNK-1) epitope that bind to anti-MAG (myelin-associated glycoprotein) IgM antibodies, and their use in diagnosis as well as for the treatment of anti-MAG neuropathy. In particular, the invention relates to disaccharides of formula (I) and (II) wherein Z is optionally substituted phenyl, heteroaryl, arylcarbonyl, or heteroarylmethyl, and to therapeutically acceptable polymers comprising a multitude of substituents of formula (I) and/or formula (II), wherein Z is a bifunctional linker connecting the disaccharides to the polymer backbone.Type: ApplicationFiled: March 12, 2015Publication date: January 26, 2017Inventors: Beat ERNST, Ruben HERRENDORFF, Andreas STECK, Fan YANG
-
Publication number: 20160361332Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).Type: ApplicationFiled: June 14, 2016Publication date: December 15, 2016Inventors: John L. Magnani, John T. Patton, Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst
-
Publication number: 20160333043Abstract: Provided herein are glycomimetic E-selectin antagonist compounds of formula (I)) and pharmaceutical compositions comprising at least one of the same. The compounds of the present disclosure include trisaccharide domain mimics comprising at least one macrocycle created through the 2nd and 3rd positions on a galactose within the mimic. Methods are also provided comprising using at least one of such compounds and compositions comprising at least one of the same to treat and/or prevent diseases and disorders treatable by inhibiting binding of an E-selectin to an E-selectin ligand.Type: ApplicationFiled: January 15, 2015Publication date: November 17, 2016Applicant: GLYCOMIMETICS, INC.Inventors: John L. MAGNANI, John M. PETERSON, Mirko ZIERKE, Martin SMIESKO, Beat ERNST
-
Publication number: 20150175644Abstract: Compounds of the formula (I) wherein n is 0, 1 or 2, R1 is aryl, heteroaryl or heterocyclyl, and R2 and R3 are hydrogen or a substituent as described in the specification, are useful for the prevention and treatment of bacterial infections, in particular of urinary infections caused by E. coli.Type: ApplicationFiled: March 6, 2015Publication date: June 25, 2015Inventors: Beat ERNST, Janno HEROLD
-
Patent number: 8921328Abstract: Compounds, compositions and methods are provided for inhibiting in vitro and in vivo processes mediated by E-selectin binding. More specifically, particular glycomimetic compounds are described, wherein the compounds are E-selectin antagonists.Type: GrantFiled: September 12, 2011Date of Patent: December 30, 2014Assignee: GlycoMimetics, Inc.Inventors: Beat Ernst, Céline E. Weckerle, Jonas K. Egger
-
Publication number: 20140178303Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).Type: ApplicationFiled: December 13, 2013Publication date: June 26, 2014Applicant: GLYCOMIMETICS, INC.Inventors: John L. Magnani, John T. Patton, JR., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst
-
Patent number: RE44778Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).Type: GrantFiled: May 30, 2012Date of Patent: February 25, 2014Assignee: Glycomimetics, Inc.Inventors: John L. Magnani, John T. Patton, Jr., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst